Positives from the article for me are the fact that Lupus is a disease with very little publicity. Hopefully awareness will increase and with a blockbuster drug, Lupozor has the potential to grab large swathes of the market with very little marketing or sales effort.
And the other positive for me is that with patients being misdiagnosed there's the possibility that the market is actually larger than we think it is. Although in saying that I don't expect it to make a major difference but a difference all the same.
It's proving to be a frustrating wait for us as shareholders but even more of a frustrating wait for clinicians and patients looking for a solution to such a horrible disease.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.